Increasingly, governments in the UK and throughout Europe see R&D driven growth as the best way out of the financial crisis. The Government identifies the 'UK’s world-class research base' as a key driver of economic growth. But does the evidence of returns from public investment in R&D match the rhetoric?
Antibacterial drug resistance is a serious and growing worldwide problem that threatens our ability to cure traditionally treatable diseases and to successfully perform numerous surgical procedures that rely on antibacterials. The current situation is due primarily to two causes: inappropriate use in humans and animals, and the decline in the development of new antibacterials, largely because of lower returns on investment in R&D. OHE has been very involved in both defining the challenge and thinking through possible responses.
This post reviews OHE's activities in September 2011 that contributed to advancing thought and stimulating innovative ideas in its three key research areas: financing and delivery of health care, HTA methods and processes, and the economics of the pharmaceutical and life sciences industries.
This is the first in a series of posts that will review OHE’s contributions to advancing thought and stimulating innovative ideas in its three key research areas: financing and delivery of health care, HTA methods and processes, and the economics of the pharmaceutical and life sciences industries.
Just published by OHE researchers is a comprehensive analysis of what policy measures are needed to counter the growing global problem of antimicrobial resistance. Their key findings are summarised in this blog post.
In October 2009, the OHE published research that compared access to orphan medicinal products (OMPs) in selected European countries. At the request of the UK Orphan Medicines Industry Group , OHE recently updated to May 2011 some of the data included in that research.
Most patients in middle and low income countries (MLICs) lack insurance coverage and so pay out of pocket for prescription medicines; pricing commensurate with income thus becomes critical to access to drugs. In this paper, the authors examine what determines the prices that manufacturers charge for originator and generic drugs across countries at all income levels.
To date, the UK Government has not been specific about how VBP will be implemented, but has indicated that calculations of value will extend beyond the QALY approach currently used by NICE. The Department of Health has stated that it will include “the range of factors through which medicines deliver benefits for patients and society”.
OHE is making available as Occasional Papers drafts of two important chapters that will appear in the Oxford Handbook on the Economics of the Pharmaceutical Industry due out in 2012. One on access to drugs and vaccines in developing countries and the other on measuring value with pharmacoeconomics.